Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Conference reports
Twice-daily bictegravir does not overcome drug interaction with rifampicin
16 April 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Reducing risk of myocardial infarction (MI) in HIV positive people
16 April 2018. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications, Coinfections and complications.
M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy
16 April 2018. Related: Conference reports, Treatment strategies, Drug resistance.
CROI 2018: second reports
30 March 2018. Related: Conference reports.
Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV
30 March 2018. Related: Conference reports, Antiretrovirals.
Statin use might reduce risk of cancer in HIV positive people
30 March 2018. Related: Conference reports, Cancer and HIV.
Rate of bone loss on ART slows after the first year
30 March 2018. Related: Conference reports, Side effects.
Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study
30 March 2018. Related: Conference reports, Pregnancy.
Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum
30 March 2018. Related: Conference reports.
Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment
30 March 2018. Related: Conference reports, Cure-related research.
25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)
14 March 2018. Related: Conference reports.
Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
14 March 2018. Related: Conference reports, Cure-related research.
No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
14 March 2018. Related: Conference reports, Cure-related research.
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
14 March 2018. Related: Conference reports, TB coinfection.
Efavirenz 400 mg can be given with anti-tuberculosis treatment
14 March 2018. Related: Conference reports, TB coinfection.
Bictegravir at CROI 2018: switching studies and drug resistance analyses
14 March 2018. Related: Conference reports, Antiretrovirals, Drug resistance.
PrEP at CROI 2018 (part 1): Access in Australia and the US
14 March 2018. Related: Conference reports, HIV prevention and transmission.
PrEP at CROI 2018 (part 2): Animal studies for future drugs
14 March 2018. Related: Conference reports, HIV prevention and transmission.
BHIVA best of CROI feedback workshops
14 March 2018. Related: Conference reports.
CROI 2018 – highlights from the preliminary programme
23 February 2018. Related: Conference reports.
16th European AIDS Conference (EACS 2017)
28 November 2017. Related: Conference reports.
Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
28 November 2017. Related: Conference reports, Antiretrovirals.
D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
28 November 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir-based dual therapy as switch option in multiple studies
28 November 2017. Related: Conference reports, Treatment strategies.
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
28 November 2017. Related: Conference reports, PK and drug interactions, TB coinfection.
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
28 November 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
28 November 2017. Related: Conference reports, Side effects.
Dolutegravir use in pregnancy: results from small Belgian cohort
28 November 2017. Related: Conference reports, Pregnancy.
No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load
28 November 2017. Related: Conference reports, Pregnancy.
Updated European guidelines launched at EACS 2017
28 November 2017. Related: Conference reports, Guidelines.
ABX464 nudges viral reservoir but not time to viral rebound
28 November 2017. Related: Conference reports, Antiretrovirals, Cure-related research.
8th International Workshop on HIV & Ageing, 2–3 October 2017, New York
28 November 2017. Related: Conference reports.
Selected webcasts from 8th HIV and ageing workshop
28 November 2017. Related: Conference reports, Ageing and life expectancy.
8th HIV and Ageing Workshop: reports at natap.org
28 November 2017. Related: Conference reports, Ageing and life expectancy.
9th IAS Conference on HIV Science (IAS 2017)
28 November 2017. Related: Conference reports.
Reassuring French data using raltegravir during pregnancy
28 November 2017. Related: Conference reports, Pregnancy.
Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high
28 November 2017. Related: Conference reports, Paediatric care.
Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold
28 November 2017. Related: Conference reports, Women's health, Pregnancy, HIV prevention and transmission.
9th IAS Conference on HIV Science (IAS 2017)
1 October 2017. Related: Conference reports.
Dual therapy with darunavir/r plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Dual therapy with dolutegravir plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir: 96-week results from the ONCEMRK study
1 October 2017. Related: Conference reports, Antiretrovirals.
New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex
1 October 2017. Related: Conference reports, HIV prevention and transmission.
On-demand dosing for PrEP is highly effective in French expanded access programme
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Psychological impact of PrEP: beyond efficacy and cost-effectiveness
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Early ART and testing HIV negative with rapid HIV tests
1 October 2017. Related: Conference reports, HIV prevention and transmission.
Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris
1 October 2017. Related: Conference reports, Cancer and HIV, Cure-related research.
9th IAS Conference on HIV Science (IAS 2017)
10 August 2017. Related: Conference reports.
HIV pipeline drugs: IAS 2017 update
10 August 2017. Related: Conference reports, Antiretrovirals.
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF
10 August 2017. Related: Conference reports, Antiretrovirals.
Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART
10 August 2017. Related: Conference reports, Antiretrovirals.
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
10 August 2017. Related: Conference reports, Antiretrovirals.
Reduced-dose darunavir is safe and effective in switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
MK-8591: further compelling early results for both treatment and prevention
10 August 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
Preliminary results on dolutegravir use in pregnancy are reassuring
10 August 2017. Related: Conference reports, Pregnancy.
Low dose efavirenz (EFV400) can be used during pregnancy
10 August 2017. Related: Conference reports, Pregnancy.
Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population
10 August 2017. Related: Conference reports, Pregnancy.
Swaziland nearly halves HIV incidence in five years
10 August 2017. Related: Conference reports, Treatment access.
Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U
10 August 2017. Related: Conference reports, HIV prevention and transmission.